These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 20194692

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
    Menéndez-Arias L, Betancor G, Matamoros T.
    Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.
    AIDS; 2002 Oct 18; 16(15):F41-7. PubMed ID: 12370521
    [Abstract] [Full Text] [Related]

  • 12. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.
    Antimicrob Agents Chemother; 2006 Aug 18; 50(8):2772-81. PubMed ID: 16870771
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
    Schuckmann MM, Marchand B, Hachiya A, Kodama EN, Kirby KA, Singh K, Sarafianos SG.
    J Biol Chem; 2010 Dec 03; 285(49):38700-9. PubMed ID: 20876531
    [Abstract] [Full Text] [Related]

  • 16. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.
    Antimicrob Agents Chemother; 2010 Apr 03; 54(4):1596-602. PubMed ID: 20124001
    [Abstract] [Full Text] [Related]

  • 17. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
    Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N.
    AIDS; 2010 Mar 13; 24(5):659-67. PubMed ID: 20160634
    [Abstract] [Full Text] [Related]

  • 18. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
    McCormick AL, Parry CM, Crombe A, Goodall RL, Gupta RK, Kaleebu P, Kityo C, Chirara M, Towers GJ, Pillay D.
    Antimicrob Agents Chemother; 2011 Apr 13; 55(4):1806-9. PubMed ID: 21282419
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.